关注
Sarit Assouline
Sarit Assouline
Jewish General Hospital
在 mcgill.ca 的电子邮件经过验证
标题
引用次数
引用次数
年份
Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ...
New England Journal of Medicine 378 (12), 1107-1120, 2018
9612018
Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
LH Sehn, AF Herrera, CR Flowers, MK Kamdar, A McMillan, M Hertzberg, ...
Journal of Clinical Oncology 38 (2), 155, 2020
7002020
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ...
Journal of the National Cancer Institute 103 (7), 553-561, 2011
5232011
Phase I clinical trial of iv ascorbic acid in advanced malignancy
LJ Hoffer, M Levine, S Assouline, D Melnychuk, SJ Padayatty, K Rosadiuk, ...
Annals of Oncology 19 (11), 1969-1974, 2008
4842008
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ...
The Lancet Oncology 21 (11), 1433-1442, 2020
4172020
Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial
S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, ...
Journal of Clinical Oncology 36 (19), 1973-1980, 2018
3462018
Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
M Andreeff, KR Kelly, K Yee, S Assouline, R Strair, L Popplewell, ...
Clinical Cancer Research 22 (4), 868-876, 2016
3392016
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin
S Assouline, B Culjkovic, E Cocolakis, C Rousseau, N Beslu, A Amri, ...
Blood 114 (2), 257-260, 2009
3392009
Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study
SM Ansell, MC Minnema, P Johnson, JM Timmerman, P Armand, ...
Journal of Clinical Oncology 37 (6), 481, 2019
3372019
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a …
MCA Palanca-Wessels, M Czuczman, G Salles, S Assouline, LH Sehn, ...
The Lancet Oncology 16 (6), 704-715, 2015
3242015
Systemic cancer therapy: achievements and challenges that lie ahead
MO Palumbo, P Kavan, WH Miller Jr, L Panasci, S Assouline, N Johnson, ...
Frontiers in pharmacology 4, 57, 2013
2952013
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
G Garcia-Manero, S Assouline, J Cortes, Z Estrov, H Kantarjian, H Yang, ...
Blood, The Journal of the American Society of Hematology 112 (4), 981-989, 2008
2932008
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
JH Lipton, C Chuah, A Guerci-Bresler, G Rosti, D Simpson, S Assouline, ...
The Lancet Oncology 17 (5), 612-621, 2016
2692016
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, ...
Annals of Oncology 28 (9), 2169-2178, 2017
2612017
DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma
IW Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, J Mayer, ...
Journal of Clinical Oncology 37 (11), 912-+, 2019
2582019
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
F Morschhauser, IW Flinn, R Advani, LH Sehn, C Diefenbach, K Kolibaba, ...
The Lancet Haematology 6 (5), e254-e265, 2019
2362019
Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
S Mori, E Vagge, P Le Coutre, E Abruzzese, B Martino, E Pungolino, ...
American journal of hematology 90 (10), 910-914, 2015
2342015
Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study
LE Budde, S Assouline, LH Sehn, SJ Schuster, SS Yoon, DH Yoon, ...
Journal of Clinical Oncology 40 (5), 481-491, 2022
2292022
Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas
RD Morin, S Assouline, M Alcaide, A Mohajeri, RL Johnston, L Chong, ...
Clinical cancer research 22 (9), 2290-2300, 2016
2282016
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
LE Budde, LH Sehn, M Matasar, SJ Schuster, S Assouline, P Giri, ...
The Lancet Oncology 23 (8), 1055-1065, 2022
2082022
系统目前无法执行此操作,请稍后再试。
文章 1–20